Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | GALR3 | O60755 | 3/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443613 | 0.85 | AGTR1 (0.59) | FFAR1PPARA | |
| SCHEMBL440513 | 0.83 | HRH3 (0.49) | FFAR1PPARAHRH3 | |
| SCHEMBL445905 | 0.78 | CA2 (0.50) | HDAC1HDAC6FFAR1PPARACA2 | |
| SCHEMBL9260111 | 0.74 | TNF (0.77) | TNFGALR3NR2F2RAB9AHDAC1 | |
| SCHEMBL6833621 | 0.73 | TNF (0.81) | TNFGALR3NR2F2RAB9AHDAC1 | |
| SCHEMBL231295 | 0.73 | TNF (1.00) | TNFGALR3NR2F2RAB9AHDAC1 | |
| Chlormidazole SCHEMBL148113 | 0.72 | GALR3 (1.00) | TNFGALR3NR2F2RAB9AHDAC1 | |
| Chlormidazole SCHEMBL30402878 | 0.72 | GALR3 (1.00) | TNFGALR3NR2F2RAB9AHDAC1 | |
| SCHEMBL1331422 | 0.72 | HDAC1 (0.74) | TNFGALR3NR2F2RAB9AHDAC1 | |
| SCHEMBL8220572 | 0.71 | TNF (0.77) | TNFGALR3NR2F2RAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | TNF 2595/4885GALR3 2661/4885NR2F2 4305/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | TNF 2595/4885GALR3 2661/4885NR2F2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.